These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21948468)

  • 1. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
    Dhar D; Toth K; Wold WS
    Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
    Dhar D; Spencer JF; Toth K; Wold WS
    J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
    Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
    Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
    Wold WS; Toth K
    Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
    Thomas MA; Spencer JF; Wold WS
    Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
    Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
    Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
    Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
    Dhar D; Toth K; Wold WS
    Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
    Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
    Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.
    Dhar D; Spencer JF; Toth K; Wold WS
    Mol Ther; 2009 Oct; 17(10):1724-32. PubMed ID: 19602998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
    Spencer JF; Sagartz JE; Wold WS; Toth K
    Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
    Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
    Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.
    Bunuales M; Garcia-Aragoncillo E; Casado R; Quetglas JI; Hervas-Stubbs S; Bortolanza S; Benavides-Vallve C; Ortiz-de-Solorzano C; Prieto J; Hernandez-Alcoceba R
    Hum Gene Ther; 2012 Dec; 23(12):1258-68. PubMed ID: 22985305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences.
    Sugio K; Sakurai F; Katayama K; Tashiro K; Matsui H; Kawabata K; Kawase A; Iwaki M; Hayakawa T; Fujiwara T; Mizuguchi H
    Clin Cancer Res; 2011 May; 17(9):2807-18. PubMed ID: 21346145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.